Meeting
2021 ASCO Annual Meeting
Clinical characteristics of SF3B1 mutant (mut) uveal melanoma (UM) and response to immune checkpoint inhibition (ICI).
Authors
Joe Grimes
Columbia University Vagelos College of Physicians and Surgeons, New York, NY
Joe Grimes , Alexander Noor Shoushtari , Marlana Orloff , Shaheer Khan , Cody Chiuzan , Susan Jean Hsiao , Diana McDonnell , Brian P. Marr , Richard D. Carvajal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 9535)
DOI
10.1200/JCO.2021.39.15_suppl.9535
Abstract #
9535
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Phase I/II study of ipilimumab plus nivolumab (IPI-NIVO) combined with sacituzumab govitecan in patients with metastatic cisplatin-ineligible urothelial carcinoma.
First Author: Rohit K. Jain
Poster
2023 ASCO Annual Meeting
Time-dependent efficacy of immune checkpoint inhibitors in the treatment of metastatic cancers: A meta-analysis.
First Author: Thierry Landre
Poster
2023 ASCO Annual Meeting
Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: An AGEO European Cohort.
First Author: Lorenzo Pilla
Poster
2023 ASCO Annual Meeting
Survival outcomes associated with liver-directed therapies in patients with metastatic uveal melanoma.
First Author: Michael M Caplan